Parexel Introduces its Connected Journey™
As life science companies continue to seek insights from data sources to make drug development more efficient and effective, Parexel International Corporation-global biopharmaceutical services provider-announced the launch of its Connected Journey of data-driven services.
Parexel's Connected Journey consists of over 40 data-driven services, including ForeSite™clinical trial methodology.
Read the full release here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
